FDA Opens Door for Moms in Medicine Testing
Published Date: 7/21/2025
Notice
Summary
The FDA just dropped new draft guidance to help include pregnant and breastfeeding women in medicine testing. This means drug makers will get clearer rules on how to safely study medicines for moms-to-be and nursing moms, so everyone gets better info on what’s safe and effective. This change could speed up research and improve health for millions, with no big cost surprises yet.
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
Guidance to Include Pregnant Participants
The FDA released draft guidance that tells drug companies general principles for running clinical trials that include pregnant women. You, as a pregnant person, could get better information about medicine safety and use because trials would explicitly include people like you.
Data on Safety, Dosing, Efficacy
The draft guidance describes approaches to generate data on safety, dosing, and how well medicines work during pregnancy and breastfeeding. If you are pregnant or breastfeeding, those approaches are intended to give doctors clearer, evidence-based information about which doses and medicines are safe and effective for you.
Recruitment and Participant Burden Guidance
The guidance includes recommendations for recruiting and keeping pregnant and breastfeeding women in clinical trials while reducing burden and harm to those participants. This means trial designs may change to make it easier and safer for pregnant and nursing people to take part.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20727, Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorganism(s) Causing Sexually Transmitted Infections Using Home-Collected Specimens
The FDA is officially classifying home test kits that detect non-viral germs causing sexually transmitted infections as Class II devices, meaning they have special safety rules but fewer hurdles than the strictest category. This change, effective October 9, 2026, helps make these tests safer and easier to get, benefiting patients and innovators alike. If you make or use these home test kits, this update means better access and clear safety standards without extra costs or delays.
Previous / Next Documents
Previous: 2025-13676, Agency Information Collection Activities: Proposed Collection; Comment Request
CMS wants your thoughts on their plan to collect info from the public and is asking for comments over the next 60 days. This helps make sure the questions they ask aren’t too much work and actually useful. If you’re someone who deals with CMS forms, this is your chance to speak up before any changes happen.
Next: 2025-13681, Morgan Stanley Pathway Funds and Consulting Group Advisory Services LLC
Morgan Stanley Pathway Funds and Consulting Group Advisory Services want permission to change their subadvisory agreements without asking shareholders every time. They’re also asking to share less info about fees paid to subadvisers. If approved, this could speed up how they manage funds, with a decision expected by mid-August 2025.